Table 2.

Adverse events for the IL-23 inhibition and placebo

IL-23 inhibition vs. placebo	No. of studies	Participants	Risk ratio	95%CI	p	Heterogeneity (I2) (%)
Patients with more than adverse event	6	2971	1.07	0.99–1.15	0.20	0
Patients with more than serious adverse event	6	2971	0.78	0.52–1.15	0.07	0
Elevated transaminases	5	2580	1.69	1.29–2.23	< 0.001	24
Infections	5	2580	0.97	0.74–1.26	0.81	62
Upper respiratory tract infection	6	2971	1.09	0.76–1.56	0.66	0
Nasopharyngitis	6	2971	1.03	0.75–1.42	0.84	0